Generic Name: idecabtagene vicleucel
Brand Name: TBC
Manufacturer: Celgene Inc., a Bristol Myers Squibb company
Therapeutic Area: Multiple myeloma
Indications: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Submission Type: Initial
Tumour Type: Myeloma
Project Status: Pending
Call for patient/clinician input open: November 19, 2020
Call for patient/clinician input closed: January 15, 2021
Anticipated Date: December 16, 2020
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.